Francisella tularensis is the causative agent of a fatal human disease, tularemia. F. tularensis was used in bioweapon programs in the past and is now classified as a category A select agent owing to its possible use in bioterror attacks. Despite over a century since its discovery, an effective vaccine is yet to be developed. In this study four transposon insertion mutants of F. tularensis live vaccine strain (LVS) in Na/H antiporter (FTL_0304), aromatic amino acid transporter (FTL_0291), outer membrane protein A (OmpA)-like family protein (FTL_0325) and a conserved hypothetical membrane protein gene (FTL_0057) were evaluated for their attenuation and protective efficacy against F. tularensis SchuS4 strain. All four mutants were 100–1000 fold attenuated for virulence in mice than parental F. tularensis. Except for the FTL_0304, single intranasal immunization with the other three mutants provided 100% protection in BALB/c mice against intranasal challenge with virulent F. tularensis SchuS4. Differences in the protective ability of the FTL_0325 and FTL_0304 mutant which failed to provide protection against SchuS4 were investigated further. The results indicated that an early pro-inflammatory response and persistence in host tissues established a protective immunity against F. tularensis SchuS4 in the FTL_0325 immunized mice. No differences were observed in the levels of serum IgG antibodies amongst the two vaccinated groups. Recall response studies demonstrated that splenocytes from the FTL_0325 mutant immunized mice induced significantly higher levels of IFN-γ and IL-17 cytokines than the FTL_0304 immunized counterparts indicating development of an effective memory response. Collectively, this study demonstrates that persistence of the vaccine strain together with its ability to induce an early pro-inflammatory innate immune response and strong memory responses can discriminate between successful and failed vaccinations against tularemia. This study describes a live attenuated vaccine which may prove to be an ideal vaccine candidate for prevention of respiratory tularemia.
Citation: Mahawar M, Rabadi SM, Banik S, Catlett SV, Metzger DW, Malik M, et al. (2013) Identification of a Live Attenuated Vaccine Candidate for Tularemia Prophylaxis. PLoS ONE 8(4): e61539. doi:10.1371/journal.pone.0061539
Editor: Yousef Abu Kwaik, University of Louisville, United States of America
Received: November 26, 2012; Accepted: March 11, 2013; Published: April 17, 2013
Copyright: © 2013 Mahawar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in whole or in part, by National Institutes of Health Grants 2P01AI056320, R56AI090072-02 (CSB) and R21AI075250-01A2 (M. Malik) and startup funds from New York Medical College (CSB) and Albany College of Pharmacy and Health Sciences (MM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Tularemia is an acute febrile disease caused by Francisella tularensis. Tularemia resulting from respiratory infection with type A F. tularensis strains is fatal and may result in 30–60% mortality in untreated cases . F. tularensis has long been considered a potential biological weapon due to its ability to cause severe illness upon inhalation and is classified as a Tier 1 category A agent by the CDC based on its possible use as a bioterror agent –. All virulent strains belong to F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B), whereas avirulent strains are classified under F. tularensis subsp. novicida or F. mediasiatica. One hundred years since its discovery, attempts to develop an effective vaccine against F. tularensis have met with limited success.
Subunit or killed vaccine against tularemia has offered limited protection against fully virulent F. tularensis –. The F. tularensis live vaccine strain (LVS), a derivative of F. tularensis subsp. holarctica was developed in the USA from the Russian strain S15 . The LVS thus far has emerged as the best vaccine candidate in rendering protection against virulent strains in human and animal studies. The LVS offered protection against subcutaneous or aerosol challenges with the virulent F. tularensis type A strains in human volunteers –. However, due to a lack of knowledge about the cause of its attenuation, residual virulence, and inadequate protection, LVS still remains an experimental vaccine. Recent studies have established that F. tularensis LVS possesses potent immunosuppressive properties and an ability to undergo phase variation which alters its protective ability . Collectively, these negative traits associated with F. tularensis LVS do not allow its use for mass immunization in its current form.
Further attenuation of LVS by genetic modifications has met with limited success against intranasal (i.n.) challenge with type A strains. We have demonstrated earlier that vaccination with a mutant of F. tularensis LVS deficient in iron-containing superoxide dismutase, SodB, could protect 40% of C57BL/6 mice against respiratory challenge with 100 CFU of F. tularensis SchuS4 . Immunization with several other attenuated mutants of F. tularensis LVS have also been shown to offer protection against F. tularensis SchuS4 strain in mice. In majority of these studies, over attenuation of LVS mutants resulted either in a complete failure or 20–40% protection in the immunized mice against an i.n. challenge. However, these mutants were found to be protective when an intradermal (i.d.) challenge route was used –. Thus, a vaccine candidate that is attenuated for virulence but still capable of inducing a potent protective immune response, particularly against the respiratory tularemia caused by F. tularensis SchuS4 needs to be developed.
Several previous studies have used attenuated mutants of Type A F. tularensis SchuS4 as vaccines and have shown protection against homologous SchuS4 challenge , . BALB/c mice when immunized with ΔFTT1103 mutant protected against i.n. challenge with 95 CFU of wild type SchuS4 . Although a defined mutant in FTT918 provided protection against i.n. challenge with virulent SchuS4 strain, the mutant itself was too virulent to be used as a vaccine . The SchuS4ΔclpB mutant provided 100% protection in i.d. immunized BALB/c mice against an i.n. challenge . In another study, a low dose immunization with the attenuated mutants of SchuS4 either by i.n. or i.d. routes protected mice from a low dose (10 CFU) i.n. challenge. Contrarily, a high dose i.d. immunization with these mutants did not protect immunized mice against a higher (200 CFU) i.n. challenge dose . The results from these studies are promising and the mutants have the potential to be developed into live attenuated vaccines. However, recent classification of F. tularensis type A strains by the CDC and Department of Health and Human Services into Tier 1 select agent category  may pose serious regulatory issues for the use of Type A F. tularensis mutants as a vaccine.
We utilized transposon mutagenesis technique to generate random insertion mutants of F. tularensis LVS and screened these mutants in macrophages for properties that correlate with attenuation of virulence (our unpublished data). We have recently reported the role of a mutant in FTL_0325 gene of LVS in F. tularensis pathogenesis. We have demonstrated that infection of macrophages with the FTL_0325 mutant results in significantly elevated levels of pro-inflammatory cytokines via enhanced activation of NF-κB . In the present study, in addition to the mutant in FTL_0325 gene which encodes for an outer membrane protein A (OmpA) like protein, we tested three other transposon insertion mutants of F. tularensis LVS in genes loci FTL_0304 (encoding for Na/H antiporter), FTL_0291 (encoding for aromatic amino acid transporter) and FTL_0057 that encodes a conserved hypothetical membrane protein for their vaccine potential against an i.n. challenge with F. tularensis SchuS4. This study reports that the identified attenuated mutants of F. tularensis LVS are safe and induce protective immunity against lethal i.n. challenge with highly virulent F. tularensis SchuS4 strain.
Materials and Methods
This study was carried out in strict accordance with the recommendations and guidelines of National Council for Research (NCR) for care and use of animals. All the animal experiments were conducted in the centralized Animal Resources Facilities of Albany Medical College and New York Medical College licensed by the USDA and the NYS Department of Health, Division of Laboratories and Research and is accredited by the American Association for the Accreditation of Laboratory Care. The use of animals and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Albany Medical College (Protocol Number 10-01003) and New York Medical College (151-2-1211.1H). Mice were administered an anesthetic cocktail consisting of ketamine (5 mg/kg) and xylazine (4 mg/kg) and underwent experimental manipulation only after they failed to exhibit a toe pinch reflex. Although, in time-to-death experiments death was intended to be used as the experimental endpoint, mice exhibiting more than 20% weight loss, anorexia, dehydration and impairment of mobility were removed from the study and euthanized by approved means. Humane endpoints were also necessary for mice which survived at the conclusion of the experiment. Mice were administered an anesthetic cocktail of ketamine and xylazine intraperitoneally (i.p.) and then euthanized via cervical dislocation followed by cardiac puncture, a method that is consistent with Albany Medical College GLP Standard Operating Procedure on “Guidelines for Animal Euthanasia” (Document Number ARF-VC-004) and recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. In all experimental procedures efforts were made to minimize pain and suffering.
F. tularensis LVS (American Type Culture Collection 29684) was provided by Dr. K. Elkins (U.S. Food and Drug Administration, Bethesda). F. tularensis SchuS4 was obtained from the U.S. Army Medical Research Institute for Infectious Diseases (Frederick) and BEI Resources (Manassas, VA). All the Francisella strains were cultured in Mueller Hinton Broth (MHB) or MH-chocolate agar plates as described previously . Mutants in FTL_0304, FTL_0291, FTL_0325 and FTL_0057 were identified as being deficient for intramacrophage growth in a transposon mutant screen of F. tularensis LVS in the alveolar macrophage cell line, MH-S (our unpublished data).
The growth characteristics of the FTL_0325 and FTL_0304 mutants grown in MHB were evaluated using high throughput assays in a 96-well plate as described earlier , . The growth curves in Brain-Heart Infusion broth (BHI) and Chamberlain’s defined medium (CDM) were prepared by growing bacteria in 25 ml culture volume following a protocol described earlier . The optical readings (OD600) were recorded at 4 hr intervals and comparisons were made with the growth attributes of wild type F. tularensis LVS grown under similar conditions.
All mouse experiments were done in accordance with the approved protocols from Institutional Animal Care and Use Committees of Albany Medical College and New York Medical College. Six to eight week old C57BL/6 and BALB/c mice (Taconic) were anaesthetized prior to inoculation via i.p. injection of a cocktail of ketamine (Fort Dodge Animal Health, Fort Dodge) and xylazine (Phoenix Scientific, St. Joseph). Mice were challenged i.n. with 1×106 or 1×107 CFU of wild type F. tularensis LVS or the mutants in 20 µl (10 µl/nare) of PBS. The infected mice were monitored twice daily for morbidity and mortality for a period of 28 days.
The bacterial numbers were quantified in the homogenates of lung, liver and spleen of mice infected with the WT F. tularensis LVS, FTL_0325 or FTL_0304 mutant at various times post-challenge as described previously . The lungs from infected mice were excised and processed using standard histological procedures. The paraffin embedded sections were stained with Hematoxylin–Eosin (H&E) and examined by light microscopy.
For protection studies, BALB/c mice were immunized i.n. with 1×107 CFU of the mutants and challenged i.n. with 100 CFU of SchuS4 in 20 µl of PBS (10 µl/nare) 30 days post-immunization. Unvaccinated mice were included as controls. The mice were observed for 21 days post-challenge for clinical signs, morbidity, and mortality. Mouse experiments with SchuS4 were carried out in the CDC certified BSL-3/ABSL-3 suite at Albany Medical College.
The protein content in the lung and spleen homogenates collected from the infected mice were normalized using a bicinchoninic protein assay kit (Pierce). Mouse Inflammation Cytometric Bead Array flex sets (BD Biosciences) were used for the simultaneous measurement of IFN-γ, TNF-α, IL-6, and MCP-1 as previously described .
Six to eight week old BALB/c mice were immunized with 1×107 CFU of the FTL_0325 or FTL_0304 mutants i.n. The mice were bled at days 45 and 60 post-infection (PI), the sera were separated and quantitated for F. tularensis specific total IgG levels by ELISA as described previously .
Determination of Recall Responses in Mice Vaccinated with the FTL_0325 and FTL_0304 Mutants
A method described earlier  was used to determine memory responses in the vaccinated mice. Briefly, BALB/c mice were immunized with 1×107 CFU of the FTL_0325 or FTL_0304 mutants by i.n. route. At 45 and 60 days post-immunization, splenocytes were collected from the immunized mice. Based on the differences in the virulence of F. tularensis LVS and SchuS4, BMDMs prepared from naive BALB/c mice were infected with 100 MOI of LVS or 20 MOI of F. tularensis SchuS4 for two hrs and treated with gentamicin (50 µg/ml) to kill the extracellular bacteria. The infected BMDMs were co-cultured with splenocytes from immunized mice in a ratio of 1∶1 for a period of 48 hrs (F. tularensis LVS infected BMDMs) and for 120 hrs (F. tularensis SchuS4 infected BMDMs). The culture supernatants were collected at the indicated times and analyzed for IFN-γ and IL-17a by BD-flex sets as described above. The BMDMs infected with F. tularensis SchuS4 and co-incubated with splenocytes from naïve, the FTL_0325 or FTL_0304 immunized mice were lysed with 0.1% sodium deoxycholate at 72 hrs PI, diluted 10-fold in sterile phosphate buffered saline (PBS) and plated on MH-chocolate agar plates (BD Biosciences) to determine the intracellular bacterial replication. The bacterial colonies were counted after 48 hrs and results were expressed as log10 CFU/ml. The experiments with F. tularensis SchuS4 were conducted in a CDC-certified BSL-3 laboratory at New York Medical College.
Results were expressed as mean ± standard error of mean (SEM) or standard deviation (SD). The comparisons between multiple groups were made using One-way Analysis of Variance (ANOVA) with Tukey-Kramer Multiple Comparisons post-test. Differences between the experimental groups were considered statistically significant at a P < 0.05 level. The survival data were analyzed using Logrank test and P-values were determined. Differences in survival between the experimental groups were considered statistically significant at a P < 0.005 level. The correlation between bacterial load and cytokine levels at days 1 and 4 in the lungs and at day 4 in the spleen were determined. The results of correlation analysis were expressed as P-value (for the hypothesis test) and an r2 value (for coefficient of determination). An r2 value of 0.6 and above was considered as a strong correlation.
The FTL_0304, FTL_0291, FTL_0325 and FTL_0057 Mutants of F. tularensis LVS are Attenuated for Virulence in Mice
The virulence of all four mutants was tested in C57BL/6 and BALB/c mice. The mice were inoculated i.n. with the mutants and wild type F. tularensis LVS, and monitored for a period of 28 days for morbidity and mortality. It was observed that all four mutants were attenuated for virulence as 100% of BALB/c or C57BL/6 survived a dose as high as 1×107 CFU inoculated i.n. On the contrary, 100% of the mice inoculated either with 1×106 or 1×107 CFU of F. tularensis LVS succumbed to infection by days 5–7 PI (Table 1). These results demonstrate that FTL_0291, FTL_0057, FTL_0304 and FTL_0325 gene products are required for virulence in mice.
Immunization with FTL_0291, FTL_0325 and FTL_0057 Protect BALB/c Mice Against F. tularensis SchuS4 Challenge
A dose as low as 1–10 CFU of F. tularensis SchuS4 strain given i.n. can cause mortality in mice within 4–6 days . BALB/c mice were immunized i.n. with 1×107 CFU of the FTL_0304 FTL_0291, FTL_0325, and the FTL_0057 mutants. A high immunization dose was chosen to avoid requirement for subsequent boosters and to evaluate the safety and efficacy of a single shot vaccine. The immunized mice were challenged with F. tularensis SchuS4 30 days post-immunization. All naïve unvaccinated mice succumbed to a 100 CFU i.n. challenge of SchuS4 with a median survival time of 6 days. Similarly, 100% of mice immunized with the FTL_0304 mutant succumbed to infection with a median survival time of 12 days which was significantly higher than the naïve unvaccinated controls. A single dose immunization with the FTL_0291, FTL_0325 and FTL_0057 mutant protected 100% of BALB/c mice against i.n. challenge with 100 CFU of F. tularensis SchuS4 and all mice survived for 21 days (Fig. 1). Survival differences between FTL_0291, FTL_0325, FTL_0057 mutants and naïve unvaccinated or FTL_0304 vaccinated mice were statistically significant when analyzed by Logrank test. These results indicate that the FTL_0291, FTL_0325 and FTL_0057 mutants retain their antigenic properties and protect the immunized mice, while immunization with the FTL_0304 mutant fails to protect mice against the F. tularensis SchuS4 challenge.
BALB/c mice (n = 10) were immunized i.n. with 1×107 CFU of the indicated mutants, challenged i.n. with 100 CFU of F. tularensis SchuS4 30 days post-immunization, and observed for mortality for a period of 21 days. Unvaccinated mice were kept as controls. Data are represented as Kaplan-Meier survival curves and are cumulative of two independent experiments. The P values were determined using Logrank test. Survival comparisons between mice immunized with the FTL_0291, FTL_0325 or FTL_0057 mutant and unvaccinated controls or FTL_0304 immunized mice are shown in the table. Differences in survival between the experimental groups were considered statistically significant at a P < 0.005 level.
The results from protection studies indicated that the mutants of F. tularensis differ in their protective capabilities against an i.n. SchuS4 challenge. We hypothesized that these variations are due to the differences in their ability to persist in the host tissue and to generate an early innate immune response. We chose the FTL_0325 mutant over FTL_0291 or FTL_0057 mutants to investigate its vaccine potential based on its ability to induce an elevated pro-inflammatory innate immune response as we have reported recently . Additionally, the FTL_0304 mutant that did not protect the immunized mice against SchuS4 challenge was also chosen to understand the differences in protective versus non-protective immune responses. These two mutants were evaluated for their ability to colonize, persist in the host tissue and to induce an inflammatory response.
The FTL_0304 and FTL_0325 Mutants of F. tularensis Exhibit no Growth Defect Under Acellular Growth Conditions
In an earlier study, we have demonstrated that the FTL_0304 and FTL_0325 mutants are attenuated for intramacrophage survival as compared to the wild type F. tularensis LVS using a macrophage cell culture invasion assay . In this study, these mutants were further characterized to understand if the intramacrophage growth defects were due to their inability to grow under acellular growth conditions. The mutants and the wild type F. tularensis LVS were inoculated in MHB, BHI broth or CDM. The OD at 600 nm was recorded over a period of 36 hrs and the growth curves were generated. It was observed that both the FTL_0325 and FTL_0304 mutants grew similar to the F. tularensis LVS in all the three growth media tested and did not reveal any growth defect (Fig. 2). These results indicate that the FTL_0304 and FTL_0325 mutants are capable of growing under acellular growth conditions and are killed only when exposed to the macrophage environment.
Growth curves for bacteria grown in MHB were generated in a 96-well plate using 200 µl culture volumes while the growth curves for bacteria grown in BHI and CDM were generated using a 25 ml culture volume. Results shown are representative of two independent experiments.
The FTL_0325 Mutant Persists Longer than FTL_0304 Mutant in Immunized Mice
BALB/c mice were infected i.n. with 1×107 CFU of F. tularensis LVS, the FTL_0304 or FTL_0325 mutant, sacrificed at days 1, 4, 7, 14 and 21 PI and the bacterial numbers recovered from lungs, liver and spleen were quantitated. Significantly lower numbers of FTL_0304 mutant were recovered as compared to the wild type F. tularensis LVS and the FTL_0325 mutant from the lungs of infected mice as early as day 1 PI; however, no differences in bacterial numbers between the latter two strains were observed at day 1 PI. The bacterial numbers in F. tularensis LVS infected mice increased significantly at day 4 PI and all mice succumbed to infection by day 7 PI (Fig. 3A). The numbers of FTL_0325 mutant strain were significantly higher than the FTL_0304 mutant at all the time-points examined; however, their numbers also declined gradually and no bacteria were recovered at day 21 PI. Dissemination of both the mutant strains to liver and spleen occurred similar to the F. tularensis LVS when observed at day 4 PI; however, the numbers of F. tularensis LVS recovered were significantly higher than those for the two mutants. Similar to the findings in lungs, the numbers of FTL_0325 mutant were significantly higher than the FTL_0304 mutant in the liver and spleen (Fig. 3B, C). The FTL_0304 mutant bacteria were observed in the liver and spleen till day 7 and 4 respectively, while the FTL_0325 mutant persisted in the spleen until day 14 PI (Fig. 3C). Taken together, these results demonstrate that the FTL_0304 mutant is highly attenuated for virulence and gets eliminated from the lungs, liver and spleen more rapidly than the FTL_0325 mutant. These results also demonstrate that the FTL_0325 mutant persists longer than the FTL_0304 mutant in infected mice.
BALB/c mice (n = 4) were infected with 1×107 CFU of the F. tularensis LVS, FTL_0325 or FTL_0304 mutant. At the indicated times, homogenates of lung (A), liver (B) and spleen (C) from the infected mice were diluted 10-fold and plated on MH-chocolate agar plates for quantification of bacterial numbers. The results are expressed as Log10 CFU/organ and are representative of two independent experiments conducted. The data were analyzed using ANOVA with Tukey-Kramer Multiple Comparison post-test and P values were recorded. *P<0.05; **P<0.01; ***P<0.001. Ψ = Mice infected with 1×107 CFU of F. tularensis LVS succumbed to infection by day 7 PI and hence were unavailable for comparison. ND = Not detected.
Immunization with the FTL_0325 Mutant Induces an Early Pro-inflammatory Cytokine Response
F. tularensis LVS dampens the innate immune response by preventing production of pro-inflammatory cytokines by the innate immune cells. We have recently reported that the macrophages infected with the FTL_0325 mutant induce significantly higher levels of pro-inflammatory cytokines than those infected either with the F. tularensis LVS or the FTL_0304 mutant . A kinetic experiment was performed to quantitate the levels of pro-inflammatory cytokines TNF-α, IL-6, MCP-1, and IFN-γ in the lung and spleen homogenates of mice infected with F. tularensis LVS, FTL_0325 or FTL_0304 mutant. Significantly higher levels of TNF-α, IL-6, and MCP-1 were observed in the lungs of FTL_0325 infected mice at day 1 PI as compared to those infected with equal numbers of wild type F. tularensis LVS or the FTL_0304 mutant (Fig. 4). As the infection progressed, the cytokine profile in the F. tularensis LVS infected mice was similar to moribund mice, wherein they exhibit a cytokine storm prior to death . In mice infected with the FTL_0325 mutant, TNF-α and IFN-γ levels peaked at day-4 PI and then returned to the baseline values. On the contrary, the FTL_0304 mutant induced extremely lower cytokine levels throughout the course of infection (Fig. 4).
BALB/c mice (n = 4) were infected with 1×107 CFU of the indicated mutants and wild type F. tularensis LVS. At the indicated times, the levels of pro-inflammatory cytokines were measured in lung homogenates using a Cytometric Bead Array assay. The data are representative of two independent experiments conducted and were analyzed using ANOVA with Tukey-Kramer Multiple Comparison post-test and P values were recorded. **P<0.01; ***P<0.001. Ψ = Mice infected with 1×107 CFU of F. tularensis LVS succumbed to infection by day 7 PI and hence were unavailable for comparison.
Significantly higher levels of TNF-α, IL-6, MCP-1 and IFN-γ were found in the spleens of FTL_0325 mutant infected mice than the FTL_0304 mutant infected mice at day 4 PI (Fig. 5). Again, the F. tularensis LVS infected mice presented a cytokine profile of moribund mice and the levels of all the cytokines tested were significantly higher than those observed for mice immunized either with the FTL_0325 or FTL_0304 mutants. No statistical correlation between bacterial numbers and MCP-1 [0.092 (P<0.33)], TNF-α [0.059 (P<0.44)] and IL-6 [0.104 (P<0.30)] cytokine responses was observed at day 1 PI in the lungs when comparisons were made between the F. tularensis LVS, FTL_0325 and FTL_0304 mutant infected mice. These results thus reflect the unique ability of the FTL_0325 mutant to induce an early pro-inflammatory cytokine response. On the other hand, a positive correlation was observed in the lungs and spleens of the F. tularensis LVS, FTL_0325 and FTL_0304 mutant infected mice at day 4 PI (Table 2). These results indicate that as the infection progresses an increase in bacterial numbers is associated with a corresponding increase in the cytokine responses. Collectively, these results demonstrate that unlike wild type F. tularensis LVS and the FTL_0304 mutant, the FTL_0325 mutant induces an early and regulated pro-inflammatory cytokine response. These findings further support the role of FTL_0325 in the modulation of pro-inflammatory cytokine responses.
BALB/c mice (n = 4) were infected with 1×107 CFU of the indicated mutants and wild type F. tularensis LVS. At the indicated times, the levels of pro-inflammatory cytokines were measured in spleen homogenates using a Cytometric Bead Array assay. The data are representative of two independent experiments conducted and were analyzed using ANOVA with Tukey-Kramer Multiple Comparison post-test and P values were recorded. *P<0.05; **P<0.01; ***P<0.001. Ψ = Mice infected with 1×107 CFU of F. tularensis LVS succumbed to infection by day 7 PI and hence were unavailable for comparison.
Immunization with the FTL_0325 Mutant Induces an Early Inflammatory Response at the Site of Infection
We next investigated if an early induction of pro-inflammatory cytokines in the mice immunized with the FTL_0325 mutant also elicits an early inflammatory response in the lungs. We examined the lung sections from mice infected with the FTL_0325 or FTL_0304 mutants. Indeed, the H&E stained lung sections from the FTL_0325 mutant-immunized mice revealed inflammatory foci consisting mostly of neutrophils as early as day 1 PI (Fig. 6 and inset). The cellular infiltration and the numbers of inflammatory foci increased at day 4 PI in the lungs of FTL_0325 mutant infected mice, which subsided gradually by day 14 PI. In contrast, the lungs of F. tularensis LVS and FTL_0304 infected mice did not exhibit any signs of cellular infiltration at day 1 PI; however, a severe inflammatory response was observed in the lungs of F. tularensis LVS infected mice at day 4 PI. Minimal to no cellular infiltration was observed in the lungs of FTL_0304 infected mice at any of the time points examined (Fig. 6). These results demonstrate that the induction of an early pro-inflammatory cytokine response in mice immunized with the FTL_0325 mutant is also associated with an early recruitment of inflammatory cells to the sites of infection in the lungs.
BALB/c mice were infected with 1×107 CFU of the F. tularensis LVS, FTL_0325 or FTL_0304 mutant and the lungs were harvested at the indicated times, sectioned and stained with H & E. Representatives of H & E stained lung sections are shown. Infiltration of neutrophils is shown in the inset (Magnification 10×; Inset 100×). Ψ = Mice infected with 1×107 CFU of F. tularensis LVS succumbed to infection by day 7 PI and hence were unavailable for comparison. Green arrows indicate the sites of cellular infiltration. Yellow circles in inset show neutrophilic infiltration in the lungs of FTL_0325 mutant immunized mice.
Immunization with the FTL_0325 or FTL_0304 Mutants Induce Similar Humoral Immune Responses
It was observed that the mice immunized with the FTL_0325 mutant were better protected against i.n. F. tularensis SchuS4 challenge than the FTL_0304 immunized mice. Moreover, mice immunized with the FTL_0325 mutant induced an early innate immune response as evidenced by the higher pro-inflammatory cytokines and an early establishment of inflammatory foci in the lungs of infected mice. Next, it was investigated if differences in the adaptive immune response also account for the better protective efficacy of the FTL_0325 mutant. F. tularensis specific IgG levels were determined at days 45 and 60 post-immunization in the sera of immunized mice by ELISA. A significantly higher level of F. tularensis specific IgG antibodies were found in the sera of mice vaccinated either with the FTL_0325 or FTL_0304 mutant as compared to the naïve mice. However, no differences were observed in the titers of total IgG antibodies between mice immunized either with the FTL_0325 or FTL_0304 mutant (Fig. 7A and B). These results suggest that the humoral immune response may not be a significant contributing factor in the enhanced protection observed in the FTL_0325 immunized mice against the F. tularensis SchuS4 challenge.
BALB/c mice (n = 3) were immunized with 1×107 CFU of the mutants intranasally. The mice were bled at days 45 (A) and 60 (B) post-immunization and total IgG levels were determined in the serum by ELISA.
Immunization with the FTL_0325 Mutant Results in a Potent Memory Recall Response
It has recently been reported that the in vivo protective ability of a vaccine can also be evaluated by observing the expression of a select group of inflammatory mediators in an ex vivo assay . We performed a splenocyte co-culture assay to establish the differences in the degree of protective efficacy observed between the mice vaccinated with the FTL_0325 and FTL_0304 mutants. BMDMs derived from naïve BALB/c mice were infected either with a 100 MOI of F. tularensis LVS or 20 MOI of F. tularensis SchuS4 for two hrs and then treated with gentamicin to kill all the extracellular bacteria. The infected BMDMs were co-cultured with splenocytes from mice immunized either with 1×107 CFU of the FTL_0325 or FTL_0304 mutant isolated at day 45 and 60 post-immunization. The co-cultures were allowed to proceed for 48 hrs for F. tularensis LVS or for 120 hrs for F. tularensis SchuS4. The cell culture supernatants were collected and analyzed for IFN-γ and IL-17a cytokines. Significantly higher levels of IFN-γ were observed in BMDMs infected either with F. tularensis LVS (Fig. 8A and B) or SchuS4 (Fig. 8E) and co-cultured with splenocytes from FTL_0325 immunized mice as compared to those observed for BMDMs co-cultured with splenocytes from FTL_0304 immunized mice. A similarly elevated level of IL-17a was also observed in BMDMs infected either with F. tularensis LVS (Fig. 8C, D) or SchuS4 (Fig. 8F) and co-cultured with splenocytes from FTL_0325 immunized mice. Concurrent with the cytokine responses, an enhanced killing of F. tularensis SchuS4 was also observed in BMDMs co-cultured with splenocytes from the FTL_0325 immunized mice (Fig. 9). These results indicate that immunization with FTL_0325 not only induces a higher degree of protection in the immunized mice but also generates an enhanced ex- vivo memory recall response at days 45 and 60 post-immunization.
Cell culture supernatants collected from BMDMs infected with either the F. tularensis LVS (A–D) or F. tularensis SchuS4 (E and F) and co-cultured with the splenocytes prepared from immunized mice at day 45 post-immunization (A and C) or at day 60 (B–F) were analyzed for IFN-γ (A, B and E) and IL-17a (C,D and F) cytokines by Cytometric Bead Flex sets. The data are representative of two independent experiments and were analyzed using ANOVA with Tukey-Kramer Multiple Comparison post-test and P values recorded. *P<0.05; **P<0.01; ***P<0.001.
The BMDMs were infected with F. tularensis SchuS4 and co-incubated with the splenocytes from naïve, FTL_0325 or FTL_0304 immunized mice. The BMDMs were lysed 72 hrs PI, diluted 10-fold and plated on MH-chocolate agar plates to determine the intracellular bacterial replication. The results were expressed as log10 CFU/ml and are representative of two independent experiments. The data were analyzed using ANOVA with Tukey-Kramer Multiple Comparison post-test and P values were recorded. ***P<0.001.
One hundred years since the discovery of F. tularensis, attempts to develop an effective vaccine against tularemia have met with limited success. Subunit or killed vaccines provided limited protection against F. tularensis SchuS4 , –. Similarly, mutants of F. tularensis LVS due to over attenuation of virulence, either failed or conferred protection only when an i.d. challenge route was used. Attenuated mutants generated on SchuS4 background have shown promising results and protected immunized mice against the fully virulent F. tularensis strains irrespective of the route of immunization , , . Although these SchuS4 mutants have the potential to be developed into live attenuated vaccines, Tier 1 Select Agent status of SchuS4 may pose serious regulatory issues for the use of these mutants for mass immunizations. Since aerosolization is the most feared route of spread of F. tularensis in a bioterror attack and based on previous observations barring two recent reports ,  that i.d. immunizations induce suboptimal protection against respiratory challenge –, in the present study i.n. immunization and challenge was preferred over the i.d. route. In this study, we describe a live attenuated vaccine candidate which is as efficacious as the SchuS4 mutants in its protective ability, along with possessing an additional advantage of being generated on the F. tularensis LVS background.
We demonstrate that all the four mutants were well tolerated by mice at a dose as high as 1×107 CFU by i.n. route which represents a 1000 LD100 for the wild type F. tularensis LVS in our laboratory. No adverse clinical signs or death was observed and necropsy of the mice sacrificed at various times PI indicated no signs of gross pathological lesions in the lungs, liver or spleen (not shown). Three of the four mutants, FTL_0325, FTL_0291 and FTL_0057 retained their immunogenic potential despite an attenuation of virulence. A single dose i.n. immunization with the FTL_0325, FTL_0291 and FTL_0057 mutants provided 100% protection against i.n. SchuS4 challenge in BALB/c mice. An immunization regimen using ten-fold less immunization dose (1×106 CFU, i.n.) did not alter the protective ability of these three mutant strains (data not shown) indicating that lower immunization doses may be equally effective in rendering protection. Interestingly, the FTL_0304 mutant which was as attenuated for virulence as the other three mutants, failed to provide protection against F. tularensis SchuS4.
We have characterized and recently reported the role of FTL_0325 and its ortholog FTT0831c in F. tularensis SchuS4 in intramacrophage survival and suppression of pro-inflammatory cytokines . In this study, we demonstrate that the FTL_0325 mutant in addition to its role in intramacrophage survival is similarly required for in vivo growth and virulence in mice. The results from this study demonstrate that although the FTL_0325 mutant survives and disseminates to multiple organs in the host, it is incapable of causing a lethal infection. Additionally, as observed in macrophages , the loss of FTL_0325 also results in the induction of pro-inflammatory cytokines as early as day 1 PI in the lungs of immunized mice. No correlation between bacterial numbers and cytokine responses at day 1 PI between F. tularensis LVS, the FTL_0325 and FTL_0304 mutant infected mice demonstrates that the observed differences in the levels of pro-inflammatory cytokines are not attributable to the differences in the bacterial load. In fact, these findings reflect the unique ability of the FTL_0325 mutant to induce an early pro-inflammatory cytokine response. Taken together, these findings support our observations that mutation of FTL_0325 leads to the loss of immune subversive properties of LVS under in vitro  as well as in vivo conditions. The increased pro-inflammatory cytokine response in the FTL_0325 immunized mice was also associated with an early influx of neutrophils, establishment of inflammatory foci and bacterial clearance. These unique characteristics of the FTL_0325 mutant meet the criteria for an ideal vaccine candidate for tularemia which as has been proposed, should lack immune-subversive properties and residual virulence of F. tularensis LVS .
The Na+/H+ antiporter encoded by the FTL_0304 gene of F. tularensis is required for the homeostasis of Na+, H+ and other monovalent cations. It has been demonstrated for several bacterial pathogens that the loss of Na+/H+ antiporters results in increased sensitivity to pH, sodium, potassium, and lithium salts, attenuation of virulence and colonization in mice , . The mutants of F. novicida  and F. tularensis SchuS4  in Na+/H+ antiporter gene are attenuated for virulence in mice and hepatic cell line, respectively. Although, transcomplementation of the FTL_0304 mutant was not performed in this study, it was observed that the transcription of genes up- and downstream of FTL_0304 was not affected as tested by quantitative real-time PCR ruling out any polar effects due to the insertion of a transposon in the FTL_0325 gene (data not shown). Our in vitro characterization results demonstrate that the FTL_0304 mutant of F. tularensis LVS does not exhibit any growth defect under acellular growth conditions but is attenuated for intramacrophage growth in MH-S cells . Further, the FTL_0304 mutant does not show an increased sensitivity towards lithium chloride, ethidium bromide or potassium chloride; however, it is sensitive to sodium chloride (data not shown). The FTL_0304 mutant appeared to be highly attenuated for virulence and significantly fewer numbers of this strain were recovered as compared to the FTL_0325 mutant throughout the course of infection. In contrast to FTL_0325, a lower induction of pro-inflammatory cytokines was observed in the lungs and spleen of the FTL_0304 mutant immunized mice. A positive correlation between the bacterial numbers and cytokine responses at day 4 PI indicates that the observed differences in cytokine responses between the FTL_0325 and FTL_0304 mutant infected mice may be a consequence of differences in the bacterial load of the organs. However, the reason for consistently lower pro-inflammatory cytokines in the FTL_0304 immunized mice is not known and remains a subject of continued investigation in our laboratory. Of the other two mutants of F. tularensis LVS used in this study, the FTL_0057 encodes for a conserved hypothetical membrane protein. This mutant has also been identified in the F. novicida genetic screen and shown to be attenuated for virulence in mice . Another mutant in FTL_0291 gene which encodes for an aromatic amino acid transporter has not been identified in any of the previous genetic screens. The roles of FTL_0057 and FTL_0291 in F. tularensis pathogenesis are not known. The results from this study demonstrate that FTL_0057 and FTL_0291 mutants of F. tularensis are attenuated for virulence in mice and provide protection against i.n. challenge with F. tularensis SchuS4 strain. A detailed investigation is warranted to examine the mechanism(s) of immune protection observed following immunization with these two mutants.
The observed differences in the protective ability of the FTL_0325 and FTL_0304 mutants strongly support the notion that in addition to an attenuation of virulence, the mutant strains should be able to persist in the host for a sufficient period of time for the induction of an effective immune response. Our in vivo studies show that the FTL_0304 mutant is highly attenuated for virulence in mice and gets cleared rapidly from the lungs, liver and spleen of the infected mice. The FTL_0304 mutant disseminates from the lungs to spleen at significantly lower numbers as compared to the FTL_0325 mutant, indicating that the mutant does not survive well in the host. A high sensitivity to salt does indicate one potential reason for its low survival and dissemination in the host. Similar to the results obtained for the FTL_0304 mutant in this study, several previous studies have also shown that highly attenuated mutants of the F. tularensis LVS carrying gene deletions of O-antigen, LPS, or the capsular capB genes, when used as vaccines did not protect BALB/c mice against an i.n. SchuS4 challenge –. In this study, significantly higher levels of F. tularensis specific IgG antibodies were produced in the mice vaccinated with the FTL_0325 or FTL_0304 mutant compared to the unvaccinated mice. The higher levels of F. tularensis specific antibodies however, fail to explain the observed differences in the protective abilities of the FTL_0325 and FTL_0304 mutants. These observations suggest that cellular immunity plays a more critical role than the antibody mediated responses to protect against a SchuS4 challenge in mice immunized with the FTL_0325 mutant. It has been reported that cell-mediated immunity acts synergistically with the humoral immune responses to provide protection against the Francisella infection , .
It has been reported that following the clearance of F. tularensis LVS, the number of cells infiltrating the lungs of vaccinated mice gradually decline and become similar to that of naïve mice. Also, Francisella specific effector memory T-cells are not continuously recruited and maintained in the lungs of these mice . Furthermore, the activities of the F. tularensis LVS primed lung and liver lymphocytes are similar to the splenocytes primed through a homologous route . Based on these observations, we used splenocytes from the immunized mice to evaluate a memory recall response. Since both the FTL_0325 and FTL_0304 mutants get cleared from the lungs of immunized mice at days 14 and 7 respectively, and the mice immunized with FTL_0325 mutant were fully protected from F. tularensis SchuS4 challenge at day 30 post-immunization, the recall responses were evaluated at days 45 and 60 post immunization to determine the duration of immunity. The hallmark of a successful vaccination is the generation of an effector memory response. Although we used the LVS based FTL_0325 mutant as a vaccine, a potent recall response was observed both against the homologous F. tularensis LVS and a heterologous F. tularensis SchuS4 strain. Our recall response studies using the LVS reaffirm the previous observations that production of IFN-γ upon recall stimulation is a hallmark of memory response against F. tularensis , . A similar observation using SchuS4 in our recall response studies indicate that IFN-γ and IL-17 responses also play an essential role in the protective immunity in the FTL_0325 immunized mice and may serve as markers for a successful vaccination strategy. Concurrent with the cytokine responses, an enhanced killing of SchuS4 by BMDMs co-cultured with the splenocytes derived from the FTL_0325 mutant immunized mice at 45 days-post immunization indicate that the immunity persists well beyond the 30 days post-challenge period used in this study. Elevated levels of IFN-γ and IL-17 upon challenge with F. tularensis SchuS4 in vaccinated mice have been shown to be associated with protection , . It has further been reported that IL-17a-dependent macrophage derived IFN-γ activates the macrophages to control the F. tularensis infection . Collectively, our results demonstrate that the recall response of splenocytes can clearly distinguish a protective and a non-protective immune response observed in the FTL_0325 versus FTL_0304 immunized mice against a F. tularensis SchuS4 challenge.
To conclude, we report that the FTL_0304, FTL_0291, FTL_0325 and FTL_0057 mutants are not only attenuated for virulence, but the latter three mutants also provide 100% protection against F. tularensis SchuS4 in immunized mice. The data from the present study clearly establish a link between the ability of mutants to persist and their inflammatory potential to their capacity to induce a protective immunity. The limited growth of FTL_0325 mutant along with its unique ability to induce an early cytokine and inflammatory response in the lungs, perhaps indicates that the host defense mechanisms triggered by this strain not only mount an effective innate immune response to terminate the bacterial infection, they also induce a long-term protective immune response. On the contrary, the rapid clearance of the FTL_0304 mutant probably due to its inability to survive in the host, results in a muted immune response insufficient to provide protection against a subsequent F. tularensis SchuS4 challenge. Collectively, this study describes a mutant in the FTL_0325 gene of F. tularensis LVS as a live attenuated candidate which may be developed into an effective vaccine against tularemia and a deletion mutant of FTL_0325 may prove useful for any potential clinical use.
Conceived and designed the experiments: CSB DWM M. Malik . Performed the experiments: M. Mahawar SMR SB SC M. Malik CSB . Analyzed the data: M. Mahawar SMR SB M. Malik CSB . Contributed reagents/materials/analysis tools: CSB DWM M. Malik . Wrote the paper: CSB M. Malik.
- 1. Sjostedt A (2007) Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 1105: 1–29. doi: 10.1196/annals.1409.009
- 2. Cronquist S (2004) Tularemia: the disease and the weapon. Dermatol Clin 22: 313–320. doi: 10.1016/j.det.2004.03.009
- 3. Bossi P, Bricaire F (2003) Tularemia, a potential bioterrorism weapon. Presse Med 32: 1126–1130.
- 4. Dennis D, Inglesby T, Henderson D, Bartlett J, Ascher M, et al. (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763–2773. doi: 10.1001/jama.285.21.2763
- 5. Biennial Review (2012) Possession, use and transfer of select agents and toxins; Final rule. Federal Register 77: 194.
- 6. Rawool D, Bitsaktsis C, Li Y, Gosselin D, Lin Y, et al. (2008) Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180: 5548–5557. doi: 10.4049/jimmunol.180.8.5548
- 7. Cole L, Yang Y, Elkins K, Fernandez E, Qureshi N, et al. (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 106: 4343–4348. doi: 10.1073/pnas.0813411106
- 8. Huntley J, Conley P, Rasko D, Hagman K, Apicella M, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664–3671. doi: 10.1128/iai.00374-08
- 9. Hickey A, Hazlett K, Kirimanjeswara G, Metzger D (2011) Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine 29: 6941–6947. doi: 10.1016/j.vaccine.2011.07.075
- 10. Conlan J (2004) Vaccines against Francisella tularensis-past, present and future. Expert Rev Vaccines 3: 307–314. doi: 10.1586/14760518.104.22.1687
- 11. Waag D, McKee K Jr, Sandstrom G, Pratt L, Bolt C, et al. (1995) Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin Diagn Lab Immunol 2: 143–148.
- 12. Saslaw S, Carlisle H (1961) Studies with tularemia vaccines in volunteers. IV. Brucella aggiutinins in vaccinated and nonvaccinated volunteers challenged with Pasteurella tularensis. Am J Med Sci 242: 166–172. doi: 10.1097/00000441-196108000-00004
- 13. Eigelsbach H, Hornick R, Tulis J (1967) Recent studies on live tularemia vaccine. Med Ann Dist Columbia 36: 282–286.
- 14. Hornick R, Eigelsbach H (1966) Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 30: 532–538.
- 15. Cowley S, Myltseva S, Nano F (1996) Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol Microbiol 20: 867–874. doi: 10.1111/j.1365-2958.1996.tb02524.x
- 16. Bakshi C, Malik M, Mahawar M, Kirimanjeswara G, Hazlett K, et al. (2008) An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26: 5276–5288. doi: 10.1016/j.vaccine.2008.07.051
- 17. Sammons-Jackson W, McClelland K, Manch-Citron J, Metzger D, Bakshi C, et al. (2008) Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA Cell Biol 27: 387–403. doi: 10.1089/dna.2007.0687
- 18. Pechous R, Celli J, Penoske R, Hayes S, Frank D, et al. (2006) Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun 74: 4452–4461. doi: 10.1128/iai.00666-06
- 19. Li J, Ryder C, Mandal M, Ahmed F, Azadi P, et al. (2007) Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 153: 3141–3153. doi: 10.1099/mic.0.2007/006460-0
- 20. Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, et al. (2005) A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun 73: 8345–8352. doi: 10.1128/iai.73.12.8345-8352.2005
- 21. Pechous R, McCarthy T, Mohapatra N, Soni S, Penoske R, et al.. (2008) A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3: e2487–
- 22. Qin A, Scott D, Thompson J, Mann B (2009) Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun 77: 152–161. doi: 10.1128/iai.01113-08
- 23. Andersson H, Hartmanova B, Kuolee R, Ryden P, Conlan W, et al. (2006) Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol 55: 263–271. doi: 10.1099/jmm.0.46313-0
- 24. Rockx-Brouwer D, Chong A, Wehrly T, Child R, Crane D, et al.. (2012) Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS ONE 7: e37752–
- 25. Mahawar M, Atianand M, Dotson R, Mora V, Rabadi S, et al. (2012) Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response. J Biol Chem 287: 25216–25229. doi: 10.1074/jbc.m112.367672
- 26. Bakshi C, Malik M, Regan K, Melendez JA, Metzger D, et al. (2006) Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol 188: 6443–6448. doi: 10.1128/jb.00266-06
- 27. Melillo A, Mahawar M, Sellati T, Malik M, Metzger D, et al. (2009) Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. J Bacteriol 191: 6447–6456. doi: 10.1128/jb.00534-09
- 28. Melillo A, Bakshi C, Melendez J (2010) Francisella tularensis antioxidants harness reactive oxygen species to restrict macrophage signaling and cytokine production. J Biol Chem 285: 27553–27560. doi: 10.1074/jbc.m110.144394
- 29. De P, Chou A, Bosio C, Huang C, Follmann D, et al.. (2012) Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog 8: e1002494–
- 30. Bell J, Owen C, Larson C (1955) Virulence of Bacterium tularense. I. A study of the virulence of Bacterium tularense in mice, guinea pigs, and rabbits. J Infect Dis 97: 162–166. doi: 10.1093/infdis/97.2.162
- 31. Chiavolini D, Alroy J, King C, Jorth P, Weir S, et al. (2008) Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun 76: 486–496. doi: 10.1128/iai.00862-07
- 32. Griffin K, Oyston P, Titball R (2007) Francisella tularensis vaccines. FEMS Immunol Med Microbiol 49: 315–323. doi: 10.1111/j.1574-695x.2007.00219.x
- 33. Landay M, Wright G, Pulliam J, Finegold M (1968) Toxicity of Pasteurella tularensis killed by ionizing radiation. J Bacteriol 96: 804–810. doi: 10.1093/infdis/119.6.635
- 34. Huntley J, Conley P, Rasko D, Hagman K, Apicella M, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664–3671. doi: 10.1128/iai.00374-08
- 35. Kadull P, Reames H, Coriell L, Foshay L (1950) Studies on tularemia. V. Immunization of man. J Immunol 65: 425–435.
- 36. Twine S, Shen H, Harris G, Chen W, Sjostedt A, et al. (2012) BALB/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine 30: 3634–3645. doi: 10.1016/j.vaccine.2012.03.036
- 37. El Sahly H, Atmar R, Patel S, Wells J, Cate T, et al. (2009) Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 27: 4905–4911. doi: 10.1016/j.vaccine.2009.06.036
- 38. Kosono S, Haga K, Tomizawa R, Kajiyama Y, Hatano K, et al. (2005) Characterization of a multigene-encoded sodium/hydrogen antiporter (sha) from Pseudomonas aeruginosa: its involvement in pathogenesis. J Bacteriol 187: 5242–5248. doi: 10.1128/jb.187.15.5242-5248.2005
- 39. Bury-Mone S, Thiberge J, Contreras M, Maitournam A, Labigne A, et al. (2004) Responsiveness to acidity via metal ion regulators mediates virulence in the gastric pathogen Helicobacter pylori. Mol Microbiol 53: 623–638. doi: 10.1111/j.1365-2958.2004.04137.x
- 40. Weiss D, Brotcke A, Henry T, Margolis J, Chan K, et al. (2007) In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci U S A 104: 6037–6042. doi: 10.1073/pnas.0609675104
- 41. Qin A, Mann B (2006) Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. BMC Microbiol 6: 69–
- 42. Conlan J, Shen H, Webb A, Perry M (2002) Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465–3471. doi: 10.1016/s0264-410x(02)00345-6
- 43. Fulop M, Manchee R, Titball R (1995) Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220–1225. doi: 10.1016/0264-410x(95)00062-6
- 44. Su J, Yang J, Zhao D, Kawula T, Banas J, et al. (2007) Genome-wide identification of Francisella tularensis virulence determinants. Infect Immun 75: 3089–3101. doi: 10.1128/iai.01865-06
- 45. Kirimanjeswara G, Golden J, Bakshi C, Metzger D (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179: 532–539. doi: 10.4049/jimmunol.179.1.532
- 46. Sebastian S, Pinkham J, Lynch J, Ross R, Reinap B, et al. (2009) Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27: 597–605. doi: 10.1016/j.vaccine.2008.10.079
- 47. Collazo C, Meierovics A, De P, Wu T, Lyons C, et al. (2009) T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun 77: 2010–2021. doi: 10.1128/iai.01322-08
- 48. Shen H, Harris G, Chen W, Sjostedt A, Ryden P, et al.. (2010) Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 5: e13349–
- 49. Kuolee R, Harris G, Conlan J, Chen W (2007) Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25: 3781–3791. doi: 10.1016/j.vaccine.2007.02.014
- 50. Khader S, Gopal R (2010) IL-17 in protective immunity to intracellular pathogens. Virulence 1: 423–427. doi: 10.4161/viru.1.5.12862
- 51. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799–810. doi: 10.1016/j.immuni.2009.08.025
- 52. Paranavitana C, Zelazowska E, Dasilva L, Pittman P, Nikolich M, et al. (2010) Th17 cytokines in recall responses against Francisella tularensis in humans. J Interferon Cytokine Res 30: 471–476. doi: 10.1089/jir.2009.0108